`
`BACHEM Bioscience, Inc.
`
`@001
`
`BACH.EM Bioscience 1nc.
`3 700 Horizon Drive
`Renaissance at Gulph Mills
`King of Prussia, PA 19406
`Tel: (610) 239--0300
`Fax: (610) 239-0800
`
`March 31, 2004
`
`Dr. Kunwar Shailubhai
`Callisto Pharmaceuticals
`7 Deer Park Dr. Suite N
`Monmouth Junction, NJ 08852
`
`Dear Shailu,
`
`We are pleased to offer you a quote for the scale up of your compound SP-304.
`We will be able to offer you a quotation for lg of peptide for $20,000. We will also
`gladly provide you with the parent compound uroguanylin at a price of $5000 for 50 mg.
`
`We are confident that the molecule, which you have chosen to pursue in your
`scale-up, will afford a much better synthetic product. We fowtd that this product was
`much better behaved during both solid-phase syntheses as weH as during folding and
`purification. As you are well aware, the urogaunylins are notorious for forming
`interconverting conformers, which are extremely difficult to purify. You have succeeded
`in developing an uroguanylin analog with superior physical properties, which is no longer
`subject to this interconversion. Therefore, the scale-up of this product will be greatly
`simplified making large-scale production viable. During our initial work on this product,
`we observed a negligible amount of the second conformer with only one primary product
`peak. Therefore, we do not anticipate any potential problem in scale up of these
`procedures for chemical synthesis and folding of the product. Purification was greatly
`simplified allowing us to offer the very favorable price above.
`
`Bachem Bioscience represents the research and development arm of the Bachem
`Group. Your project should it require cGMP manufacturing can easily be transferred
`within our organization and receive the same priority treatment as you have already
`experienced with us.
`
`~drell~ Pennington, Ph.D.
`President and C.0.0,
`
`<
`
`PrlnftdD1'1rw,'Cllad1
`
`Bausch Health Ireland Exhibit 2040, Page 1 of 1
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`